NeurogesX Reports Second Quarter 2009 Results
... of the PDUFA date can trigger a three-month extension
to the original review timeline. On August 5, ... of Qutenza in Europe. In the U.S., the PDUFA date extension
for Qutenza in PHN was not unexpected given the ... as a favorable result with only a three-month extension
to our PDUFA date. With Astellas as our partner, ...
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
... with postherpetic neuralgia (PHN).
resulted from the Company's recent submission of ... of the PDUFA date can trigger a three-month extension
to the original review timeline.
Anthony ... and CEO, commented, "The FDA's three-month extension
is not unexpected. We previously discussed the ...
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
... primary endpoint over one year of treatment in an extension
study in patients with predominant, persistent ...
About the study
This study was a 26-week extension
of a randomized, double-blind, multicentered, ... double-blind treatment regimen for the 26-week extension
study. In ...
Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science
... Aaron Hager, associate professor and weed science extension
specialist with the University of Illinois, ... Knake with its very first "Outstanding extension
Award" and named him a Fellow for his ...
Though Knake spent his career in academia and extension
work, he paved the way for a new generation of ...
Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
... the Exchange and the Company has been granted an extension
until August 11, 2009 to regain compliance with ... to periodic review by Exchange staff during the extension
period. Failure to make progress consistent with ... the continued listing standards by the end of the extension
period could result in the Company being delisted ...
SENOMYX ANNOUNCES FIRST QUARTER 2009 FINANCIAL RESULTS
... in the coffee and coffee whitener fields
of discovery and development program with Ajinomoto Co., Inc.
of collaborative research and license agreement ... and no debt.
"Senomyx started 2009 with the extension
of our collaborative agreements with Ajinomoto ...
Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union
... the option of entering
a one year open label extension
ESL demonstrated significant and ... Acetate (ESL): Results of a One-Year
to Study BIA-2093-302. Poster presented at the ... Acetate (ESL): Results of a One-Year
to Study BIA-2093-303. Poster presented at the ...
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
... today positive results from its ongoing Phase 2 extension
study of its investigational drug, Amigal(TM) ... 2009 Annual Meeting in Tampa, FL.
Phase 2 extension
Twenty-six subjects ... continue to receive treatment in an ongoing extension
study designed to evaluate the long term safety ...
Weed Science Society of America Announces Winners in Annual Scientific Awards Program
Fort Collins, Colorado
- Outstanding extension
Award for an individual exhibiting excellence in weed science extension
Chris Boerboom, Ph.D.
Professor and extension
University of Wisconsin-Madison ...
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
... 2 studies continue to be treated in a voluntary extension
study to characterize the long-term safety and ... and dose regimens. Amicus expects data from this extension
study to be available in the first quarter of ... an 11-week treatment period with an optional extension
study. The objectives of the trial include the ...
NYSE Alternext US Accepts China Shenghuo's Compliance Plan for Continued Listing
... the Company's Plan and granted the Company an extension
November 19, 2008 to file the Form 10-Q and ... to
periodic review by Exchange staff during the extension
period. Failure to
make progress consistent with ... the
continued listing standards by the end of the extension
period could result
in the Company being delisted ...
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
... Phase 3 and Open Label extension
Results Support Efficacy and Safety ... interim results of the uncontrolled open
(OLE) study were included as well. The data ... interim results from the ongoing Open Label extension
(OLE) (GOUT 3)
study for Puricase(R) ...
Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
... conclusion of the hearing
process and during any extension
period which may be granted by the Panel.
It is ... and that the
Panel has discretion to grant an extension
not to exceed 180 days from the
date of the Staff ... Listing Qualifications Panel or in
obtaining any extension
from such Panel, and that it may continue to ...
Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
... Three-Year extension
for Integrated Drug Discovery Support in the ... Disease drug discovery programs. This
is worth up to US$ 37 million in research ... grown significantly. In addition
to the contract extension
announced today, the companies also have ...
Montana State University lab gives early warnings about biological invaders
... together for an interactive workshop using an MSU extension
In a sense, the network has built ... or, potentially, human health. They also train extension
agents, crop advisors and master gardeners to ... of the national system, when an ag producer, extension
agent or consultant detects a suspicious pest in ...
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
... GlaxoSmithKline announced
today results from the extension
arm of a Phase II study on its
first-in-class, ... and of the 51 patients enrolled in
arm with TYKERB plus capecitabine, eight remained ... Of the 51 patients enrolled in the extension
arm, 10 (20 percent) who
received TYKERB plus ...
Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
... abdominal pain, fatigue, and diarrhea. Phase 3 extension
96-week study for Naglazyme (galsulfase) ... 27 at 8:15am -- Pivotal, Phase 3 open-label extension
study reported safety and efficacy data of ... pivotal Phase 3 trial, followed by a 72-week extension
study for a total of 96 weeks. -- Endpoints ...
Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
Provides Members of University HealthSystem ... company, has signed a new two-year
on behalf of UHC valued at over $200 million over the
contract term. The extension
will commence at the conclusion of UHC's
Coherent, Inc. Receives Expected Letter from NASDAQ
... on February 15, 2007 to request an extension
listing on the NASDAQ Global Select ... a decision granting the Company a conditional extension
to file its
Form 10-K for the fiscal year ended ... that the Listing Council will grant an extension
listing. Shares of Coherent common ...
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
... Inc. (Nasdaq: TPTX ) today announced a one year extension
its research agreement with Eisai Co., Ltd. that was entered into on
October 1, 2005. The extension
marks the continuation of Eisai's support ... and Chief Executive
Officer of TorreyPines. "The extension
of our collaboration with Eisai not
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
... Patients in this randomized placebo-controlled study with open-label extension
conducted under the supervision of lead investigator, Prof. Frans M.J. ... the ongoing Phase 3 study, until the end of 2011. Patients entering this extension
study sponsored by the Company's partner sanofi-aventis, will be ...
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
... end of 52 weeks, 345 patients chose to participate in an optional 24-week extension
phase of the study, during which all patients received belimumab. At Week ... email@example.com or by calling HGS at (301) 610-5790, extension
HGS, Human Genome Sciences, ABthrax, Albuferon, BENLYSTA and ...
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
... the ongoing Phase 3 study, until the end of 2011. Patients entering this extension
study will be followed-up for safety, International Prostate Symptom Score ... Patients in this randomized placebo-controlled study with open-label extension
conducted under the supervision of lead investigator, Prof. Frans M.J. ...
YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
... to the same period in the prior year is mainly attributable to a 12 month extension
of the revenue recognition period for the initial payment from one of YM's ... same period in the prior year is mainly as a result of the above mentioned extension
and the ending of monthly revenue recognition for one other deferred ...
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
... development. These analyses include data from patients in the ongoing extension
of the DURATION-1 study who used exenatide once weekly produced at ... or not achieving the intended clinical endpoints; the DURATION-1 study extension
results potentially not being accepted to support comparability; label ...
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
... (NDA) submitted to FDA. These analyses include data from the ongoing extension
of the DURATION-1 study, and will be used to support comparability between ... or not achieving the intended clinical endpoints; the DURATION-1 study extension
results potentially not being accepted to support comparability; ...
SENOMYX ANNOUNCES THE EXTENSION OF ITS COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT WITH AJINOMOTO CO., INC.
... the food, beverage, and ingredient supply industries, announced today the extension
of one of its discovery and development programs with Ajinomoto Co., Inc., ... containing any flavor ingredients developed under the agreement. This extension
does not impact the companies' activities with existing flavor ingredients ...
Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
... the expiration of the subsequent offering period.
During the extension
of the subsequent offering period, BTB will accept for payment and ... shares into the offer.
Procedures for tendering shares during this extension
of the subsequent offering period shall be the same as during the ...
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
... December 2008, the Company filed for approval of a TPIAO label
for the treatment of idiopathic thrombocytopenic purpura
(ITP) ... 36,000 IU dosage formulation of EPIAO,
NuLeusin, and TPIAO label extension
for the treatment of ITP.
-- Initiate Ferumoxytol registration trial ...
Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference
Life cycle extension
About Campbell ... Campbell Alliance
Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
... signing of $3.1 million of new business awards, primarily consisting of an extension
of a current U.S. oncology clinical trial with a major global pharmaceutical company to be conducted in the U.S. and Europe. The extension
increases the value of the contract from $12.4 million to $14.4 million.
Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
... with Eslicarbazepine Acetate (ESL): Results of a One-Year
to Study BIA-2093-302. Poster presented at the American
Epilepsy Society ... with Eslicarbazepine Acetate (ESL): Results of a One-Year
to Study BIA-2093-303. Poster presented at the American
Epilepsy Society ...
Isis Reports Financial Results and Highlights for Third Quarter of 2008
... patients -- Provide an update on mipomersen from an ongoing open-label extension
study in patients with FH -- Report Phase 2 study data in type 2 ... or fatty liver. Additionally, we will provide an update on our
study where we have patients who have been exposed to
mipomersen from ...
deCODE genetics Announces Third Quarter 2008 Financial Results
... Market pending the conclusion of the hearing process and during any extension
period which may be granted by the Panel. It is expected that the hearing would be held within 45 days. The Panel has discretion to grant an extension
not to exceed 180 days from the date of the Staff notification for the ...
deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
... Global Market pending the conclusion of the hearing process
and during any extension
period which may be granted by the Panel. It is
expected that the hearing would be held within 45 days. The Panel has
discretion to grant an extension
not to exceed 180 days from the date of
the Staff notification for the ...
Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
... equity in order to remain listed. The Company has
requested an extension
to December 3, 2008 to comply with this requirement
and to achieve its ... However, there
can be no assurance that the Company will be granted this extension
The NASDAQ Capital Market is one of the three market tier ...
Osage Bio Energy Kicks Off 'Barley Bin Builder' Yield Contest
... looking forward to working with state
grain organizations and land grant extension
services in the Barley Bin
Builder Yield Contest.
Farmers in Delaware, ... in excess of 120 bushels
per acre," said Wade Thomason, Virginia Tech extension
"The Barley Bin Builder Yield Contest gives us a great ...
NicOx Reports Results for the First Three Quarters of 2008
... long term safety demonstrated for both doses of naproxcinod in the 301 extension
study, with no unexpected safety findings. In addition, the patients' ... pressure, as well
as by the good long term safety data observed in the 301 extension
We have also significantly advanced our pre-launch activities ...
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
... -- Galenea Corp. and
Otsuka Pharmaceutical Co., Ltd. announced today the extension
of their research and development collaboration. The two ... nervous system (CNS)
diseases. The new agreement calls for a one year extension
of the initial
five-year alliance and brings the total committed funding ...
BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
... Product Line extension
Builds on Existing Brand Strength and Pediatric ... our multivitamin granule product.
Pediatric multivitamins is an ideal extension
of our GoodBaby brand as it
builds on our existing brand strength and ...